3007 related articles for article (PubMed ID: 22487441)
1. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
3. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
4. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score.
Schiavina R; Borghesi M; Brunocilla E; Manferrari F; Fiorentino M; Vagnoni V; Baccos A; Pultrone CV; Rocca GC; Rizzi S; Martorana G
BJU Int; 2013 Jun; 111(8):1237-44. PubMed ID: 23331345
[TBL] [Abstract][Full Text] [Related]
5. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
Briganti A; Joniau S; Gontero P; Abdollah F; Passoni NM; Tombal B; Marchioro G; Kneitz B; Walz J; Frohneberg D; Bangma CH; Graefen M; Tizzani A; Frea B; Karnes RJ; Montorsi F; Van Poppel H; Spahn M
Eur Urol; 2012 Mar; 61(3):584-92. PubMed ID: 22153925
[TBL] [Abstract][Full Text] [Related]
6. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
[TBL] [Abstract][Full Text] [Related]
7. Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years.
Suardi N; Ficarra V; Willemsen P; De Wil P; Gallina A; De Naeyer G; Schatteman P; Montorsi F; Carpentier P; Mottrie A
Urology; 2012 Jan; 79(1):133-8. PubMed ID: 22088567
[TBL] [Abstract][Full Text] [Related]
8. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors.
Joniau S; Hsu CY; Gontero P; Spahn M; Van Poppel H
Scand J Urol Nephrol; 2012 Jun; 46(3):164-71. PubMed ID: 22364377
[TBL] [Abstract][Full Text] [Related]
11. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
Isbarn H; Wanner M; Salomon G; Steuber T; Schlomm T; Köllermann J; Sauter G; Haese A; Heinzer H; Huland H; Graefen M
BJU Int; 2010 Jul; 106(1):37-43. PubMed ID: 20002667
[TBL] [Abstract][Full Text] [Related]
12. Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience.
Busch J; Stephan C; Herold A; Erber B; Kempkensteffen C; Hinz S; Lein M; Weikert S; Miller K; Magheli A
BJU Int; 2012 Dec; 110(11 Pt C):E985-90. PubMed ID: 22672442
[TBL] [Abstract][Full Text] [Related]
13. Long-term oncological outcomes after laparoscopic radical prostatectomy.
Hruza M; Bermejo JL; Flinspach B; Schulze M; Teber D; Rumpelt HJ; Rassweiler JJ
BJU Int; 2013 Feb; 111(2):271-80. PubMed ID: 22757970
[TBL] [Abstract][Full Text] [Related]
14. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
15. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
16. Tumour characteristics, oncological and functional outcomes in patients aged ≥ 70 years undergoing radical prostatectomy.
Kunz I; Musch M; Roggenbuck U; Klevecka V; Kroepfl D
BJU Int; 2013 Mar; 111(3 Pt B):E24-9. PubMed ID: 22947135
[TBL] [Abstract][Full Text] [Related]
17. The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients.
Schiavina R; Bertaccini A; Franceschelli A; Manferrari F; Vagnoni V; Borghesi M; Morselli-Labate AM; Martorana G
Anticancer Res; 2010 Jun; 30(6):2297-302. PubMed ID: 20651383
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era.
Dorin RP; Daneshmand S; Lassoff MA; Cai J; Skinner DG; Lieskovsky G
Urology; 2012 Mar; 79(3):626-31. PubMed ID: 22245303
[TBL] [Abstract][Full Text] [Related]
19. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
[TBL] [Abstract][Full Text] [Related]
20. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.
Mitchell CR; Boorjian SA; Umbreit EC; Rangel LJ; Carlson RE; Karnes RJ
BJU Int; 2012 Dec; 110(11):1709-13. PubMed ID: 22934913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
